Abstract
In the introduction to our article (Pediatrics, 34:795, 1964) it is clearly stated that one inoculation of live measles vaccine is the immunization of choice for infants over 9 months of age. This regimen has obvious advantages over the combined inactivated-live measles vaccination procedures which entail multiple inoculations. On the other hand, live vaccine is not consistently immunogenic for younger infants because of the potential suppressive effect of residual passive antibody. Passively acquired measles antibody may disappear as early as 3 months or as late as 11 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
